127 related articles for article (PubMed ID: 37867340)
21. Predictive Immunohistochemical Markers Related to Drug Selection for Patients Treated with Sunitinib or Sorafenib for Metastatic Renal Cell Cancer.
Ma X; Wang L; Li H; Zhang Y; Gao Y; Guo G; Liu K; Meng Q; Zhao C; Wang D; Song Z; Zhang X
Sci Rep; 2016 Aug; 6():30886. PubMed ID: 27488093
[TBL] [Abstract][Full Text] [Related]
22. CD31 angiogenesis and combined expression of HIF-1α and HIF-2α are prognostic in primary clear-cell renal cell carcinoma (CC-RCC), but HIFα transcriptional products are not: implications for antiangiogenic trials and HIFα biomarker studies in primary CC-RCC.
Biswas S; Charlesworth PJ; Turner GD; Leek R; Thamboo PT; Campo L; Turley H; Dildey P; Protheroe A; Cranston D; Gatter KC; Pezzella F; Harris AL
Carcinogenesis; 2012 Sep; 33(9):1717-25. PubMed ID: 22777959
[TBL] [Abstract][Full Text] [Related]
23. Sunitinib inhibition of Stat3 induces renal cell carcinoma tumor cell apoptosis and reduces immunosuppressive cells.
Xin H; Zhang C; Herrmann A; Du Y; Figlin R; Yu H
Cancer Res; 2009 Mar; 69(6):2506-13. PubMed ID: 19244102
[TBL] [Abstract][Full Text] [Related]
24. [Effect of Bushen Chushi() decoction combined with platelet-rich plasma on regulating TGF-β1 and Smad-1 expression in serum of knee osteoarthritis patient].
Di DX; Ai Q; Yan Q; Li Y; Zhang HM; Chen L; Tang XN
Zhongguo Gu Shang; 2023 Jul; 36(7):647-53. PubMed ID: 37475629
[TBL] [Abstract][Full Text] [Related]
25. A novel FBW7/NFAT1 axis regulates cancer immunity in sunitinib-resistant renal cancer by inducing PD-L1 expression.
Liu W; Ren D; Xiong W; Jin X; Zhu L
J Exp Clin Cancer Res; 2022 Jan; 41(1):38. PubMed ID: 35081978
[TBL] [Abstract][Full Text] [Related]
26. A novel therapeutic strategy of combined camrelizumab and apatinib for the treatment of advanced hepatocellular carcinoma.
Yang Q; Li G; Wu X; Lin H; Wu W; Xie X; Zhu Y; Cai W; Shi C; Zhuo S
Front Oncol; 2023; 13():1136366. PubMed ID: 37064142
[TBL] [Abstract][Full Text] [Related]
27. Sunitinib in patients with metastatic renal cell carcinoma: Birmingham experience.
Ansari J; Fatima A; Fernando K; Collins S; James ND; Porfiri E
Oncol Rep; 2010 Aug; 24(2):507-10. PubMed ID: 20596640
[TBL] [Abstract][Full Text] [Related]
28. Clinical Efficacy of Yiqi Yangyin Decoction Combined with Docetaxel on Advanced Ovarian Cancer and the Effect on the Levels of Serum Markers VEGF, HE4, and CA125.
Wang N; Xiao F; Shao H; Shi S; Zhou Y
J Healthc Eng; 2022; 2022():8401202. PubMed ID: 35368946
[TBL] [Abstract][Full Text] [Related]
29. [Clinical study of yiqi huoxue recipe in the treatment of liver fibrosis of chronic viral hepatitis].
Cui LY; Zhang XX; Cui P; Li WC; Zhang YG; Wang RQ; Zhao SX; Ren WG; Kong LL; Han F; Yuan XW; Liu LD; Zhang Y; Zhang QS; Kong L; Nan YM
Zhonghua Gan Zang Bing Za Zhi; 2020 May; 28(5):403-409. PubMed ID: 32536056
[No Abstract] [Full Text] [Related]
30. Analysis of efficacy of sorafenib combined with vascular endothelial growth factor inhibitor on renal cell carcinoma.
Wang Q; Qin J; Liu X
J BUON; 2019; 24(4):1638-1643. PubMed ID: 31646819
[TBL] [Abstract][Full Text] [Related]
31. Efficacy and Safety of Fuzheng Yiqi Kang-Ai Decoction Combined with External Irradiation in the Treatment of Undifferentiated Thyroid Carcinoma and Its Influence on Antiangiogenesis.
Bian L; Zhang J; Wang P
J Oncol; 2022; 2022():3589924. PubMed ID: 35615246
[TBL] [Abstract][Full Text] [Related]
32. [Governor vessel moxibustion combined with
Gao WZ; Sun ZX; Chen X; Li PC
Zhongguo Zhen Jiu; 2023 Jan; 43(1):40-4. PubMed ID: 36633238
[TBL] [Abstract][Full Text] [Related]
33. Prospective study assessing hypoxia-related proteins as markers for the outcome of treatment with sunitinib in advanced clear-cell renal cell carcinoma.
Garcia-Donas J; Leandro-García LJ; González Del Alba A; Morente M; Alemany I; Esteban E; Arranz JA; Climent MA; Gallardo E; Castellano DE; Bellmunt J; Mellado B; Puente J; Moreno F; Font A; Hernando S; Robledo M; Rodríguez-Antona C
Ann Oncol; 2013 Sep; 24(9):2409-14. PubMed ID: 23788753
[TBL] [Abstract][Full Text] [Related]
34. Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial.
Motzer RJ; Rini BI; McDermott DF; Arén Frontera O; Hammers HJ; Carducci MA; Salman P; Escudier B; Beuselinck B; Amin A; Porta C; George S; Neiman V; Bracarda S; Tykodi SS; Barthélémy P; Leibowitz-Amit R; Plimack ER; Oosting SF; Redman B; Melichar B; Powles T; Nathan P; Oudard S; Pook D; Choueiri TK; Donskov F; Grimm MO; Gurney H; Heng DYC; Kollmannsberger CK; Harrison MR; Tomita Y; Duran I; Grünwald V; McHenry MB; Mekan S; Tannir NM;
Lancet Oncol; 2019 Oct; 20(10):1370-1385. PubMed ID: 31427204
[TBL] [Abstract][Full Text] [Related]
35. Immune Biomarkers Predictive for Disease-Free Survival with Adjuvant Sunitinib in High-Risk Locoregional Renal Cell Carcinoma: From Randomized Phase III S-TRAC Study.
George DJ; Martini JF; Staehler M; Motzer RJ; Magheli A; Escudier B; Gerletti P; Li S; Casey M; Laguerre B; Pandha HS; Pantuck AJ; Patel A; Lechuga MJ; Ravaud A
Clin Cancer Res; 2018 Apr; 24(7):1554-1561. PubMed ID: 29374054
[No Abstract] [Full Text] [Related]
36. Diagnosis Value of Colposcope Combined with Serum Squamous Cell Carcinoma Antigen, Carbohydrate Antigen 125, and Carcinoembryonic Antigen for Moderate to Advanced Cervical Cancer Patients Treated with Modified Fuzheng Peiyuan Decoction.
Meng H; Zhang Y; Chen Y
Evid Based Complement Alternat Med; 2021; 2021():4355805. PubMed ID: 35003300
[TBL] [Abstract][Full Text] [Related]
37. Renal Functional Outcome of Partial Nephrectomy for Complex R.E.N.A.L. Score Tumors With or Without Neoadjuvant Sunitinib: A Multicenter Analysis.
McDonald ML; Lane BR; Jimenez J; Lee HJ; Yim K; Bindayi A; Hamilton ZA; Field CA; Bloch AS; Dey S; Noyes S; McKay R; Millard F; Rini BI; Campbell SC; Derweesh IH
Clin Genitourin Cancer; 2018 Apr; 16(2):e289-e295. PubMed ID: 29113767
[TBL] [Abstract][Full Text] [Related]
38. Association of Expression Levels or Activation Status of STAT3 with Treatment Outcomes of Sunitinib in Patients with Renal Cell Carcinoma.
Yamamoto K; Hara T; Nakagawa T; Hirai M; Miyake H; Fujisawa M; Yano I
Target Oncol; 2018 Jun; 13(3):371-378. PubMed ID: 29633072
[TBL] [Abstract][Full Text] [Related]
39. Allosteric inhibition of HIF-2α as a novel therapy for clear cell renal cell carcinoma.
Yu Y; Yu Q; Zhang X
Drug Discov Today; 2019 Dec; 24(12):2332-2340. PubMed ID: 31541711
[TBL] [Abstract][Full Text] [Related]
40. Diagnostic Value of Serum Markers Combined with TVCDS in Ovarian Cancer Patients Treated with Bushen Yiqi Quyu Prescription.
Qin W; Jiang F; Zhang T
Evid Based Complement Alternat Med; 2021; 2021():3522906. PubMed ID: 34917157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
